Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 21, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

[PSA kinetics after radiotherapy].

J-M Riedinger1, N Eche, J-M Bachaud

  • 1Département de biologie et de pathologie des tumeurs, Laboratoire de biologie clinique, Centre Georges François Leclerc, Dijon. j.riedinger@dijon.fnclcc.fr

Annales De Biologie Clinique
|August 7, 2009
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dihydropyrimidine dehydrogenase phenotype-guided dose individualization of fluoropyrimidine in gastrointestinal cancers: PRODIGE100-UCGI48-FUDOSE phase II study.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·2026
Same author

[Moderately hypofractionated dose escalation radiotherapy for localized prostate cancer, ESHYPRO: Results of a retrospective single-centre series evaluating safety and efficacy].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2024
Same author

Salvage low-dose-rate brachytherapy for locally recurrent prostate cancer after definitive irradiation.

Clinical and translational radiation oncology·2024
Same author

[Does radiation therapy for prostate cancer increase the risk of second cancers?]

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2024
Same author

Indication and perspectives of radiation therapy in the setting of de-novo metastatic prostate cancer.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2023
Same author

[Early detection of prostate cancer: Towards a new paradigm?]

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2023
Same journal

[The role of the heart-on-a-chip to drug evaluation].

Annales de biologie clinique·2026
Same journal

A morphology-driven proof-of-concept study linking interphase nuclear abnormalities to dicentric-mediated genomic instability.

Annales de biologie clinique·2026
Same journal

Analytical validation and clinical concordance of Diazyme free light chain assays on the Cobas® platform compared with Freelite™.

Annales de biologie clinique·2026
Same journal

Small-cell secondary plasma cell leukemia mimicking low-grade B-cell lymphoma.

Annales de biologie clinique·2026
Same journal

[Multiple myeloma and analytical discrepancy in serum free light chain assay: a case report].

Annales de biologie clinique·2026
Same journal

[Summary of the 34th National Conference of the National College of Hospital Biochemistry].

Annales de biologie clinique·2026
See all related articles

Prostate specific antigen (PSA) monitoring after radiotherapy is crucial for detecting prostate cancer recurrence. Dynamic PSA changes, not just thresholds, predict outcomes and recurrence site after treatment.

Area of Science:

  • Oncology
  • Biochemistry
  • Urology

Context:

  • Prostate specific antigen (PSA) is a key biomarker for prostate cancer.
  • Current interpretation often relies on thresholds, which can be limiting.
  • Dynamic PSA monitoring is essential for accurate assessment.

Purpose:

  • To emphasize the dynamic interpretation of PSA levels post-radiotherapy.
  • To define biochemical recurrence based on PSA nadir and increase.
  • To explore the diagnostic value of recurrence timing and PSA doubling time.

Summary:

  • PSA levels typically decrease post-radiotherapy, reaching a nadir <1 microg/L, indicating recurrence-free survival.
  • Biochemical recurrence is defined as a 2 microg/L rise above PSA nadir, with or without endocrine therapy.

Related Experiment Videos

Last Updated: Jun 21, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

  • The timing of recurrence and PSA doubling time after radiotherapy can help determine if recurrence is local or metastatic.

    • Impact:

    • Highlights the importance of dynamic PSA interpretation over static thresholds.
    • Provides clear definitions for biochemical recurrence after radiotherapy.
    • Establishes the prognostic value of PSA kinetics in predicting recurrence site.